1. Home
  2. CVKD vs WNW Comparison

CVKD vs WNW Comparison

Compare CVKD & WNW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

HOLD

Current Price

$1.08

Market Cap

3.9M

Sector

Health Care

ML Signal

HOLD

Logo Meiwu Technology Company Limited

WNW

Meiwu Technology Company Limited

N/A

Current Price

$2.36

Market Cap

4.5M

ML Signal

N/A

Company Overview

Basic Information
Metric
CVKD
WNW
Founded
2022
2015
Country
United States
China
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Catalog/Specialty Distribution
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
3.9M
4.5M
IPO Year
2022
2019

Fundamental Metrics

Financial Performance
Metric
CVKD
WNW
Price
$1.08
$2.36
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$13.00
N/A
AVG Volume (30 Days)
1.2M
474.5K
Earning Date
05-08-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
23.94
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$1.14
Revenue Growth
N/A
N/A
52 Week Low
$1.00
$0.05
52 Week High
$14.64
$13.52

Technical Indicators

Market Signals
Indicator
CVKD
WNW
Relative Strength Index (RSI) 22.65 44.02
Support Level N/A $2.30
Resistance Level $2.23 $3.31
Average True Range (ATR) 0.17 0.15
MACD -0.01 0.00
Stochastic Oscillator 5.43 5.65

Price Performance

Historical Comparison
CVKD
WNW

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

About WNW Meiwu Technology Company Limited

Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments including Clean Food platform, Skincare products & service and Technical Service. The company generates the majority of its revenue from Technical services.

Share on Social Networks: